 |
|
HPV L1 VLP vaccine V504
A vaccine formulation consisting of several types of human papillomavirus (HPV)-derived noninfectious virus-like particles (VLPs) with potential immunoprophylactic activity. Upon administration, HPV L1 VLP vaccine V504 may generate humoral immunity against various HPV L1 major capsid proteins, thereby preventing cervical infection upon exposure to the associated HPV types. VLPs are composed of self-assembling L1 major capsid proteins or functional L1 major capsid protein derivatives. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | V504 | | |
| Previous: | HLA-A1, A2, B35-restricted survivin peptides/Montanide ISA-51 vaccine, HLA-A2, A3-restricted FGF-5 peptides/Montanide ISA-51 vaccine, Hodgkin's antigens-GM-CSF-expressing cell vaccine, HPPH, HPV 16 E7:86-93 peptide vaccine | | Next: | Hsp27 antisense oligonucleotide OGX-427, Hsp90 antagonist KW-2478, Hsp90 inhibitor AUY922, Hsp90 inhibitor SNX-5422 mesylate, HspE7 |
|
|
